Each type may follow different submission and review processes depending on the primary mode of action (PMOA). Familiarity with regulations set forth by the FDA, EMA, and other regional regulatory authorities is essential in this initial step.

Documentation expectations: Document the definitions, classifications, and relevant laws from the FDA, EMA, and other significant health authorities, ensuring that all team members are aligned on the terminology and implications. This may include reviewing documents such as:

• FDA’s guidance on combination products.
• Relevant EU regulations and directives.
• Guidelines from leading agencies including WHO and Health Canada.

Step 2: Assessing Regulatory Pathways for Renewals

Once the definitions and classifications are understood, the next step is to assess the appropriate regulatory pathways for renewals and re-registrations. In the U.S., different submission types (e.g., NDA, BLA, PMA, or 510(k)) may apply depending on the components and intended use of the combination product.

When determining the correct pathway, consider the following factors:

• Primary mode of action: Identify the most significant therapeutic effect to determine which type of submission is necessary.
• Product modifications: Determine if changes in manufacturing, formulation, or design necessitate new submissions or the categorization of post-approval changes.
• Post-market surveillance requirements: A strong post-market surveillance (PMS) plan must be in place to manage ongoing reporting obligations during the product lifecycle.

Documentation expectations: Maintain a comprehensive comparison chart outlining each submission type in relation to your product, clearly noting submission timelines, requirements, and expected regulatory review periods.

Step 3: Preparing for Submission and Documentation Requirements

Preparation is key for successful renewals. This phase demands meticulous documentation outlining both regulatory compliance and product efficacy. Start by consolidating existing documentation relevant to clinical data, quality processes, and device specifications.

For regulatory submissions, consider the following important documents:

• Clinical trial summaries and data examples which highlight safety and effectiveness.
• Quality Manufacturing System documentation that outlines compliance with Good Manufacturing Practices (GMP).
• Risk management documentation ensuring that all potential risks have been assessed and mitigated.
• Change control records to validate and justify modifications to the combination product.

Once all documents are prepared, compile them in accordance with regulatory guidelines. For example, in the U.S., the FDA specifies detailed requirements for electronic submissions via the Electronic Common Technical Document (eCTD) format. Prepare distinct sections for each aspect of your submission to facilitate regulatory review.

Documentation expectations: Create a checklist to ensure all required documents are completed and reviewed. Include clear timelines for document collection, reviews, and final sign-off, ensuring all team members understand their responsibilities. Use templates when available to standardize the documentation process.

Step 4: Submission and Interaction with Regulatory Authorities

The actual submission is a critical phase in renewing and re-registering combination products. As you submit the application, ensure that both electronic and hard copies, if required, are fully completed and accurate. During this phase, it may also be beneficial to engage the FDA or other regulatory bodies through pre-submission meetings, offering clarification on your product and submission approach.

Key actions to take during submission include:

• Ensuring that the submission adheres to regulatory agency guidelines and, if necessary, includes a request for expedited pathways such as Breakthrough Therapy or Fast Track Designation.
• Having all team members adequately prepared for potential regulatory queries during review, which may involve additional data requests or clarifications.
• Documenting all interactions with regulatory authorities and maintaining a formal log with updates on any discussions or agreements reached during the review process.

Documentation expectations: Maintain a submission log that documents submission dates, received acknowledgement from regulatory authorities, and timelines for responses. This should also include any feedback received during the review process for future reference.

Step 5: Post-Approval Commitments and Change Management

Upon successful renewal of a combination product, the responsibilities do not end there. Continuous monitoring and compliance with post-approval commitments are vital for product lifecycle management. Develop a robust plan for post-market surveillance and risk management that incorporates ongoing PMS activities, adverse event reports, and device upgrades.

Consider the following key points when establishing your post-approval strategies:

• Establishing a system for capturing complaints and implementing corrective actions. Ensure that detailed records are kept of how issues are resolved and that direct communication with users or patients is appropriately documented.
• Developing a change control process that complies with regulatory requirements. This may involve submitting changes concerning device upgrades, manufacturing processes, or updates to clinical data, all of which should be effectively communicated to the regulatory authorities.
• Regularly auditing the product against the latest regulatory requirements, including updates to ICH-GCP and local regulations.

Documentation expectations: Prepare a post-approval commitments document outlining PMS activities, complaint management systems, change control processes, and periodic review dates. Establish clear timelines for reporting outcomes or submitting additional information for long-term product compliance.

Step 6: Continuous Regulatory Readiness and Improvement

Finally, the last step involves establishing a culture of continuous regulatory readiness. In an environment characterized by constant change in regulations, being proactive in compliance can mitigate risks associated with renewals and re-registrations. Train team members regularly on regulatory updates, emerging trends, and improving product management processes.

Actions to consider for fostering regulatory readiness include:

• Regular training sessions that incorporate changes to regulations or guidance, ensuring that the team maintains current knowledge of their respective roles and responsibilities.
• Creating a regulatory intelligence strategy that ensures prompt dissemination of new regulatory information, including updates from major global health organizations and regulatory authorities.
• Establish systems to routinely benchmark your product against competitors, using insights to inform ongoing development and regulatory strategies.

Documentation expectations: Develop a continuous improvement plan delineating the processes and timelines for training, monitoring, and reviewing regulatory performance. Establish clear accountability across the organization to reinforce the importance of compliance and proactive management of combination products.